FDA Panel Backs Pfizer Inc. Vaccine for Adults
Published: Nov 17, 2011
A panel of federal health experts voted overwhelmingly Wednesday to recommend that Pfizer's best-selling vaccine be approved for a new use in preventing pneumococcal disease in adults age 50 and older. The Food and Drug Administration's vaccine panel voted 14-1 that data supports Pfizer's Prevnar 13 as a safe and effective vaccine for preventing the bacterial infection in adults. Pneumococcal disease causes meningitis, pneumonia and ear infection. Prevnar 13 protects against 13 strains of the disease and is already a standard vaccination for infants and young children, who are most vulnerable to infection.